Potential Role of Bone Metabolism Markers in Kidney Transplant Recipients

• Published in: Current medicinal chemistry Vol. 31; no. 19; p. 2809
• Main Authors: Vigil, Flávia Maria Borges, Vaz de Castro, Pedro Alves Soares, Hasparyk, Ursula Gramiscelli, Bartolomei, Victória Soares, Simões E Silva, Ana Cristina
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.01.2024
• Subjects: Adaptor Proteins, Signal Transducing; Adult; Biomarkers - blood; Bone and Bones - metabolism; Cross-Sectional Studies; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors - blood; Humans; Intercellular Signaling Peptides and Proteins - blood; Kidney Transplantation; Male; Middle Aged; Osteocalcin - blood; Osteopontin - blood; Osteoprotegerin - blood; Renal Dialysis; hemodialysis; chronic kidney disease; bone metabolism; biomarkers; renal osteodystrophy; Kidney transplantation
• ISSN: 1875-533X
• DOI: 10.2174/0109298673250291231121052433

The impact of treatments, suppressing the immune system, persistent hyperparathyroidism, and other risk factors on mineral and bone disorder (MBD) after kidney transplantation is well-known. However, there is limited knowledge about their effect on bone metabolism biomarkers. This study aimed to investigate the influence of kidney transplant on these markers, comparing them to patients undergoing hemodialysis and healthy individuals. In this cross-sectional study, three groups were included: kidney transplant patients (n = 57), hemodialysis patients (n = 26), and healthy controls (n = 31). Plasma concentrations of various bone metabolism biomarkers, including Dickkopf-related protein 1, osteoprotegerin, osteocalcin, osteopontin, sclerostin, and fibroblast growth factor 23, were measured. Associations between these biomarkers and clinical and laboratory data were evaluated. A total of 114 patients participated. Transplant recipients had significantly lower levels of Dickkopf-related protein 1, osteoprotegerin, osteocalcin, osteopontin, sclerostin, and fibroblast growth factor 23 compared to hemodialysis patients. Alkaline phosphatase levels positively correlated with osteopontin (r = 0.572, < 0.001), while fibroblast growth factor 23 negatively correlated with 25-hydroxyvitamin D (r = -0.531, = 0.019). The panel of bone biomarkers successfully predicted hypercalcemia (area under the curve [AUC] = 0.852, 95% confidence interval [CI] = 0.679-1.000) and dyslipidemia (AUC = 0.811, 95% CI 0.640-0.982) in transplant recipients. Kidney transplantation significantly improves mineral and bone disorders associated with end-stage kidney disease by modulating MBD markers and reducing bone metabolism markers, such as Dickkopf-related protein 1, osteoprotegerin, osteocalcin, osteopontin, and sclerostin. Moreover, the panel of bone biomarkers effectively predicted hypercalcemia and dyslipidemia in transplant recipients.